4-(2-氯乙氧基)-苯甲腈 | 72081-00-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-氯乙氧基)-苯甲腈
• 英文名称: 3-(2-chloroethoxy)benzonitrile
• 英文别名: 4-chloroethoxybenzonitrile；4-(2-chloroethoxy)benzonitrile
• CAS: 72081-00-6
• 化学式: C₉H₈ClNO
• 分子量: 181.622
• InChiKey: UYFJDKPCZDFWPF-UHFFFAOYSA-N

物化性质

• 沸点：
  318.1±17.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2-氯乙氧基)-苯甲腈 、 二乙胺 在 potassium carbonate 、 potassium iodide 作用下， 以 2-甲基-2-丁醇 为溶剂， 反应 22.0h， 以97.5 mg的产率得到4-[2-(二乙氨基)乙氧基]苯甲腈
  参考文献：
  名称：

  钯催化的芳族和杂芳族氯化物的氯乙氧基化：氯乙氧基接头的正交官能化†

  摘要：

  设计了一种基于交叉偶联化学的新型断开连接，以获取药学上相关的芳基-氨基乙基醚。用四（2-氯乙氧基）硼酸钠钠开发的钯催化的芳基和杂芳基氯化物的官能化与乙烯接头的氯官能团的简单亲核取代正交。该转化在不存在额外的外部碱的情况下实现了有效的2-氯乙氧基化。烷基卤的随后胺取代得到2-氨基乙氧基芳烃。通过合成各种芳基和杂芳基烷基醚，包括市售药物分子的中间体，证明了该方法的适用性。

  DOI：

  10.1039/c8ob01146j
• 作为产物：
  描述：

  对氯苯甲腈 、 sodium tetrakis(2-chloroethoxy)borate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 2-甲基-2-丁醇 为溶剂， 反应 18.0h， 生成 4-(2-氯乙氧基)-苯甲腈
  参考文献：
  名称：

  钯催化的芳族和杂芳族氯化物的氯乙氧基化：氯乙氧基接头的正交官能化†

  摘要：

  设计了一种基于交叉偶联化学的新型断开连接，以获取药学上相关的芳基-氨基乙基醚。用四（2-氯乙氧基）硼酸钠钠开发的钯催化的芳基和杂芳基氯化物的官能化与乙烯接头的氯官能团的简单亲核取代正交。该转化在不存在额外的外部碱的情况下实现了有效的2-氯乙氧基化。烷基卤的随后胺取代得到2-氨基乙氧基芳烃。通过合成各种芳基和杂芳基烷基醚，包括市售药物分子的中间体，证明了该方法的适用性。

  DOI：

  10.1039/c8ob01146j

文献信息

• [EN] SMALL MOLECULE MENIN INHIBITORS<br/>[FR] INHIBITEURS DE MÉNINE À PETITES MOLÉCULES
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2020072391A1

  公开（公告）日：2020-04-09

  The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R1c, E, G, and Q are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin.

  本公开提供由以下公式I表示的化合物及其药用可接受的盐和溶剂化物，其中R1a、R1b、R1c、E、G和Q的定义如规范中所述。本公开还提供公式I的化合物用于治疗癌症或对抑制menin敏感的任何其他疾病、症状或障碍。
• Design and synthesis of ERα/ERβ selective coumarin and chromene derivatives as potential anti-breast cancer and anti-osteoporotic agents
  作者：M. Kamil Hussain、M. Imran Ansari、N. Yadav、Puneet K. Gupta、A. K. Gupta、R. Saxena、I. Fatima、M. Manohar、P. Kushwaha、V. Khedgikar、J. Gautam、Ruchir Kant、P. R. Maulik、R. Trivedi、A. Dwivedi、K. Ravi Kumar、A. K. Saxena、K. Hajela

  DOI：10.1039/c3ra45749d

  日期：——

  Several new coumarin and chromene prototype derivatives have been synthesised and evaluated for their ERα and ERβ selective activity. Coumarin prototype compounds 18 & 19 were found to be ERα selective and the most active, exhibiting potential antiproliferative activity against both ER +ve & ER −ve breast cancer cell lines. The surprise finding of the series, however, are the novel prototype III chromenes 45 & 46, with aroyl substitution at the 6th position. Both the compounds have shown potent antiproliferative activity against both the breast cancer cell lines, promote alkaline phosphatase activity, enhance osteoblast mineralization in vitro, significantly decrease ERE–ERα dependent transactivation and induce ERβ activity. This specific upregulation of ERβ isoform activity of compound 45 may be responsible for the antiosteoporotic activity at picomolar concentration. In addition, both the compounds were also devoid of any estrogenic activity, which correlates to their antiestrogenic behaviour in the two breast cancer cell lines. Assessment of selectivity using specific SiRNAs for ERα and ERβ revealed that most of the compounds showed ERα and ERβ-mediated action, except compound 28, which showed selectivity to ERα only. Computational docking analysis of active compounds 18 and 45 was conducted to correlate the interaction with the two receptors and it was found that the docked conformations of the coumarin prototype, compound 18 at ERα and ERβ active sites were more or less superimposable on each other. However, the unique orientation of the aminoalkoxy side chain of novel chromene (prototype III) compound 45 in the ERβ binding cavity may be responsible for its potential biological response.

  我们合成了几种新的香豆素和色烯原型衍生物，并对它们的ERα和ERβ选择性活性进行了评估。研究发现，香豆素原型化合物 18 和 19 具有ERδ选择性，活性最强，对ER+ve 和 ER âve 乳腺癌细胞系都具有潜在的抗增殖活性。然而，该系列的惊喜发现是新型原型 III 色烯化合物 45 和 46，其第 6 位被酰基取代。这两种化合物对两种乳腺癌细胞系都有很强的抗增殖活性，能促进碱性磷酸酶活性，增强体外成骨细胞矿化，显著降低EREâERα依赖性转录活化并诱导ERβ活性。化合物 45 对ERδ同工酶活性的这种特异性上调可能是其在皮摩尔浓度下具有抗骨质疏松活性的原因。此外，这两种化合物也没有任何雌激素活性，这与它们在两种乳腺癌细胞系中的抗雌激素作用有关。利用特异性 SiRNA 对 ERα 和 ERβ 的选择性进行评估后发现，除化合物 28 仅对 ERα 具有选择性外，大多数化合物都具有 ERα 和 ERβ 介导的作用。对活性化合物 18 和 45 进行了计算对接分析，以确定其与两种受体的相互作用，结果发现香豆素原型化合物 18 在 ERα 和 ERβ 活性位点的对接构象或多或少可以相互叠加。不过，新型香豆素（原型 III）化合物 45 的氨基烷氧基侧链在 ERβ 结合腔中的独特取向可能是其潜在生物反应的原因。
• Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles
  作者：Peter E. Cross、Roger P. Dickinson、M. John Parry、Michael J. Randall

  DOI：10.1021/jm00148a009

  日期：1985.10

  1-(2-Phenoxyethyl)-1H-imidazole was found to be an inhibitor of thromboxane (TxA2) synthetase, but it also inhibited the adrenal cytochrome P-450 enzyme steroid 11 beta-hydroxylase. The preparation of a series of analogues is described, and activity against TxA2 synthetase, PGI2 synthetase, cyclooxygenase, and steroid 11 beta-hydroxylase is discussed. Potency against TxA2 synthetase was increased by introduction of a carboxyl group at a suitable distance from the imidazole ring. A distance of 8.1-8.8 A between N-1 of the imidazole and the carboxyl carbon was found to be optimal. Introduction of a carboxyl group also had the effect of reducing activity against steroid 11 beta-hydroxylase. The most potent and selective compound was found to be 4-[2-(1H-imidazol-1-yl) ethoxy]benzoic acid (14).
• NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF
  申请人：TOYAMA CHEMICAL CO., LTD.

  公开号：EP1481966B1

  公开（公告）日：2011-07-20
• MIZUNO KAZUHIKO; KIMURA YOSHIKAZU; OTSUJI YOSHIO, SYNTHESIS, 1979, NO 9, 688
  作者：MIZUNO KAZUHIKO、 KIMURA YOSHIKAZU、 OTSUJI YOSHIO

  DOI：——

  日期：——